| __timestamp | CRISPR Therapeutics AG | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 20707000 |
| Thursday, January 1, 2015 | 12573000 | 17831000 |
| Friday, January 1, 2016 | 42238000 | 18047000 |
| Sunday, January 1, 2017 | 69800000 | 11033000 |
| Monday, January 1, 2018 | 113773000 | 13432000 |
| Tuesday, January 1, 2019 | 179362000 | 52072000 |
| Wednesday, January 1, 2020 | 266946000 | 51488000 |
| Friday, January 1, 2021 | 438633000 | 85727000 |
| Saturday, January 1, 2022 | 461645000 | 95518000 |
| Sunday, January 1, 2023 | 387332000 | 125046000 |
| Monday, January 1, 2024 | 320653000 |
Unlocking the unknown
In the rapidly evolving biotech sector, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, CRISPR Therapeutics AG and Geron Corporation have demonstrated contrasting R&D strategies. CRISPR Therapeutics AG, a pioneer in gene editing, has consistently increased its R&D budget, peaking in 2022 with a 30-fold increase since 2014. This reflects their commitment to advancing CRISPR technology. In contrast, Geron Corporation, focused on telomerase-based therapies, has maintained a more conservative R&D approach, with a 6-fold increase over the same period. Notably, in 2023, Geron Corporation's R&D spending surged by 31% compared to the previous year, indicating a potential strategic pivot. These trends highlight the dynamic nature of biotech investments and the varying approaches companies take to drive innovation.
Research and Development Investment: AstraZeneca PLC vs Geron Corporation
Amgen Inc. vs Geron Corporation: Strategic Focus on R&D Spending
R&D Insights: How Biogen Inc. and CRISPR Therapeutics AG Allocate Funds
Research and Development Expenses Breakdown: Axsome Therapeutics, Inc. vs Geron Corporation
Comparing Innovation Spending: Verona Pharma plc and Geron Corporation
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Arrowhead Pharmaceuticals, Inc.
Comparing Innovation Spending: CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated
R&D Spending Showdown: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
R&D Insights: How Perrigo Company plc and Geron Corporation Allocate Funds
Veracyte, Inc. vs Geron Corporation: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Protagonist Therapeutics, Inc. vs Geron Corporation
Research and Development Expenses Breakdown: Geron Corporation vs Wave Life Sciences Ltd.